|
|
Capricor Therapeutics inc (CAPR) |
|
Price: $2.9900
$-0.01 
-0.333%
|
| Day's High:
| $3
| Week Perf:
| 0.67 %
|
| Day's Low: |
$ 2.93 |
30 Day Perf: |
6.6 % |
| Volume (M): |
144 |
52 Wk High: |
$ 8.22 |
| Volume (M$): |
$ 431 |
52 Wk Avg: |
$4.39 |
| Open: |
$3.00 |
52 Wk Low: |
$2.68 |
|
|
| Market Capitalization (Millions $) |
77 |
| Shares
Outstanding (Millions) |
26 |
| Employees |
11 |
| Revenues (TTM) (Millions $) |
14 |
| Net Income (TTM) (Millions $) |
-29 |
| Cash Flow (TTM) (Millions $) |
1 |
| Capital Exp. (TTM) (Millions $) |
1 |
Capricor Therapeutics Inc
Capricor Therapeutics Inc. is a clinical-stage biotechnology company headquartered in Los Angeles, California, founded in 200 Capricor Therapeutics is focused on the development of innovative cell-based therapies for the treatment of cardiovascular and other diseases. The company's core technology is based on the mesenchymal stem cells (MSCs).
Capricor Therapeutics has developed a proprietary platform for the isolation, manufacturing, and delivery of MSCs. These cells are derived from the bone marrow, fat tissue, or placenta of healthy donors. The platform also includes a process for culturing MSCs that is designed to maximize their therapeutic potential.
Capricor Therapeutics is currently conducting clinical trials of its lead product candidate, CAP-1002, which is an allogeneic cell therapy consisting of MSCs. CAP-1002 is being evaluated in multiple indications, including Duchenne muscular dystrophy (DMD), cardiac diseases, and pulmonary arterial hypertension. The company has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration (FDA) for CAP-1002 in DMD.
Capricor Therapeutics also has a range of preclinical programs focused on the discovery and development of new cell-based therapies for the treatment of other diseases, including neurological disorders.
In addition to its own research and development efforts, Capricor Therapeutics has collaborations with several academic institutions and industry partners. The company is financially supported by a combination of government grants, private investors, and partnerships.
Overall, Capricor Therapeutics is a biotechnology company that is focused on developing innovative cell-based therapies for the treatment of cardiovascular and other diseases. The company's MSC-based platform technology has the potential to address significant unmet medical needs, and it is currently being evaluated in multiple clinical trials.
Company Address: 10865 Road to the Cure, Suite 150, San Diego San Diego 92121 CA
Company Phone Number: 727-1755 Stock Exchange / Ticker: NASDAQ CAPR
| CAPR is expected to report next financial results on March 16, 2024. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals Inc, a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections, recently announced its financial results for the July to September 30, 2023, period. During this period, the company reported an increase in losses, which expanded from $1.27 per share a year prior to $1.32 per share. However, it is worth noting that the earnings per share (EPS) improved from -$1.86 in the preceding reporting period.
The revenue for the same period decreased by 6.817% to $18.93 million compared to $20.32 million in the previous reporting period. While sequentially, the revenue advanced slightly by 0.212% from $18.89 million. This decline in revenue could raise concerns, as it may indicate slowing demand for Enanta Pharmaceuticals Inc's products.
|
|
Procyon Corporation
Based on the financial time-frame ending September 30, 2023, Procyon Corporation has experienced significant declines and challenges, leading to a bearish outlook for the company. Depleting orders have played a crucial role in the losses incurred during this period.
The revenue for Procyon Corporation fell by -0.221% to $1.17 million compared to the previous reporting season, where revenue decreased by -2.42% from $1.20 million. This downward trend indicates a constant struggle for the company to maintain a steady revenue stream. It is clear that Procyon Corporation has been facing difficulties in generating consistent income.
|
|
China Health Industries Holdings Inc
China Health Industries Holdings Inc (CHHE) recently announced its financial results for the fiscal period ending September 30, 2023. These results demonstrate the company's ability to achieve top-line growth despite industry-wide revenue reductions. Additionally, CHHE's inventories have declined, indicating potential future demand. This article will outline the facts and set the current financial results into context.
Financial Results Overview:
For the fiscal period ending September 30, 2023, CHHE reported a zero gain of $0.00 per share, compared to a loss of $0.01 per share during the same period a year ago. Sequentially, CHHE improved from a loss of $0.01 per share in the previous quarter. This indicates progress in generating profits and more favorable financial performance.
|
|
Acer Therapeutics Inc
The stock performance of a company plays a vital role in determining its overall financial health. Acer Therapeutics Inc, a major player in the pharmaceutical preparations industry, has experienced a decline in its stock price over the past week, negatively impacting its year-to-date performance. This article aims to provide an overview of the recent trends seen in Acer Therapeutics Inc's stock performance, along with insights into the company's financial records and future expectations.
Stock Performance
Over the past week, Acer Therapeutics Inc's stock has experienced a decline, although the exact percentage decrease is undisclosed in the provided information. This downtrend has brought the company's year-to-date performance to a staggering -74.81%. Consequently, investors may have concerns about the company's financial stability, prompting a closer examination of its financial records.
|
|
Baudax Bio Inc
Baudax Bio Inc, a pharmaceutical company listed on the NASDAQ, recently released its financial results for the July to September 2023 period. The company demonstrated significant improvements in its loss per share and earnings per share compared to the previous year and the previous quarter. Despite revenue remaining unchanged, Baudax Bio Inc reported a substantial decrease in its net shortfall. This article aims to outline the facts and interpret these financial results.
1. Improving Financial Performance:
For the July to September 2023 period, Baudax Bio Inc managed to decrease its loss per share from $-2.47 to $-0.30 when compared to the same quarter last year, showcasing a remarkable improvement. Moreover, earnings per share saw significant growth from $-1.51 in the previous quarter to the current quarter.
|
| Per Share |
Current |
| Earnings (TTM) |
-1.14 $ |
| Revenues (TTM) |
0.54 $
|
| Cash Flow (TTM) |
0.02 $ |
| Cash |
1.1 $
|
| Book Value |
-
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.14 $
|
| Revenues (TTM) |
0.54 $ |
| Cash Flow (TTM) |
0.02 $ |
| Cash |
1.1 $
|
| Book Value |
- |
| Dividend (TTM) |
0 $ |
|
|
|
|
